Tiziana Life Sciences Ltd stock is traded at $0.621, with a volume of 359,637. It is up +1.77% in the last 24 hours and down -43.03% over the past month. Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Previous Close:
$0.6102
Open:
$0.64
24h Volume:
359,637
Relative Volume:
0.48
Market Cap:
$79.03M
Revenue:
-
Net Income/Loss:
-$18.43M
P/E Ratio:
-
EPS:
-$0.1558
Net Cash Flow:
-$12.87M
1W Performance:
+0.10%
1M Performance:
-43.03%
6M Performance:
-60.19%
1Y Performance:
-65.11%
1-Day Range:
$0.6099$0.6572
1-Week Range:
$0.6099$0.6998
52-Week Range:
$0.5671$1.90
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS